Immunotherapy with Bacillus Calmette-Guérin (BCG) to treat non-muscle invasive bladder cancer has become an effective and superior alternative to chemotherapy. Intravesical treatment with BCG appears to be relatively safe; however, occasionally BCG infection complicates such treatment. In the present work we describe three patients in whom BCG infection occurred after intravesical BCG therapy. ...

When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose give, and 2) for how long? The issue optimal duration has been subject several randomized trials is especially pertinent in context a global BCG shortage. Despite this, there appears uncertainty as whether or may c...

Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis that has been widely used for the treatment of superficial transitional cell carcinoma of the bladder. We describe a rare case of supra-renal mycotic aortic aneurysm secondary to BCG instillation in a 75-year-old male. Patients presenting with systemic symptoms post-instillation, possibly with an aneurysm, should ...

2014 Bacillus Calmette-Guérin (BCG) is a vaccine derived from attenuated strains of Mycobacterium bovis. Mycobacterium bovis BCG-based therapy is considered an effective alternative for bladder carcinoma in situ when exclusive transurethral resection is inadequate. Among the complications associated with therapy, there are few reports in the literature on reactive arthritis. We report the case ...

Disseminated mycobacterial infection after Bacille Calmette-Guérin (BCG) vaccination is a rare disorder, usually presenting with fever, weight loss, anemia, lymphadenopathy and hepatosplenomegaly. We report a case of disseminated BCG infection in a 28-month-old girl with prolonged fever and abdominal mass due to retroperitoneal abscess. Appropriate therapy resulted in a good response. This is t...

Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial bladder carcinoma. We report a case of disseminated BCG infection in an early stage bladder cancer patient that initially presented with hepatitis followed by pneumonitis and sepsis. A complete clinical response was achieved in 14 days with anti-mycobacterial therapy and prednisolone. Dissemin...

In high-burden countries, Mycobacterium bovis Bacillus Calmette-Guérin (BCG) vaccine is administered in newborn to prevent severe Mycobacterium tuberculosis infection. Because life-threatening disseminated BCG disease may occur in children with primary immunodeficiency, vaccination strategy against tuberculosis should be redefined in non-high-burden countries. We report the case of a patient wi...

Bacillus Calmette and Guérin (BCG) was introduced to Japan in 1924 by Kiyoshi Shiga and has been propagated for research purposes ever since propagation is accomplished using a glycerin-bile-potato mixture in the same manner used by Calmette and Guérin. To prepare a stable and safe freeze-dried BCG vaccine, several joint research projects were organized in 1949. At the National Institute of Inf...

The spectacular failure of the existing bacille Calmette-Guérin (BCG) vaccine in recent tuberculosis-control trials has prompted a search for potential replacements. Imaginative approaches currently under development include the modulation of BCG by the production of auxotrophic mutants or cytokine-secreting recombinants, and the development of subunit vaccines based on the major proteins of My...

There is strong evidence that tuberculin sensitivity cannot be used to evaluate the efficacy of different strains of bacille Calmette-Guérin (BCG). For identifying efficacious strains of BCG and evaluating candidates for new vaccines, the best method is a randomized trial. Simple trials in which newborns would be vaccinated with new and old vaccines in alternate years could demonstrate which va...